Search for content, post, videos

Nykode announces positive final results from its Phase 2 trial

Michael Engsig and Agnete Fredriksen
Nykode Therapeutics has announced results from the VB-C-02 trial, investigating the use of Nykode’s therapeutic cancer vaccine candidate VB10.16 in combination with Roche’s cancer immunotherapy Tecentriq in patients with advanced or recurrent, non-resectable HPV16-positive cervical cancer.
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.